Search Results

Eczema, or atopic dermatitis (AD), is a chronic inflammatory skin condition marked by skin barrier dysfunction and immune dysregulation. Driven by genetic, immunological and environmental factors, as well as skin microbiome changes, emerging research suggests live biotherapeutic products (LBPs) could revolutionise its treatment and prevention. What We Know: During AD flare-ups, microbial diversity declines and Staphylococcus aureus  often dominates. Up to 70% of individuals with AD have S. aureus  colonisation on lesional skin and 30%–40% on non-lesional skin. A disrupted skin barrier, due to genetic and environmental factors, increases pH and water loss, creating conditions for S. aureus overgrowth (Totté et al., 2016). The severity of AD symptoms correlates with S. aureus  levels, exacerbated by toxins like δ-toxin and PSMα. Notably, many AD patients’ microbiomes lack gram-negative bacteria, further reducing microbial diversity (Locker et al., 2024). LBPs, defined as live organisms used to prevent, treat, or cure diseases, offer a novel approach to addressing these imbalances (Ağagündüz et al., 2022). Industry Impact and Potential: LBPs show promise by targeting S. aureus  overgrowth and improving skin health. Examples include Roseomonas mucosa  and coagulase-negative staphylococci (e.g., Staphylococcus hominis  A9), which reduce S. aureus  through antimicrobial and immune-modulating mechanisms. Furthermore, Nitrosomonas eutropha  B244 produces anti-inflammatory nitrite, showing potential to alleviate AD  symptoms(Locker et al., 2024). @Concerto Bioscience recently initiated a Phase 1 trial of Ensemble No.2 (ENS-002), a topical LBP targeting S. aureus overgrowth. ENS-002 employs three microbial strains to address the root microbial deficiencies linked to AD. Designed for topical application, it minimises systemic risks like immune suppression or infections (Andrus, 2024). ENS-002’s development leveraged Concerto's kChip screening technology, which tests millions of microbial combinations to uncover interactions that modulate skin health. Using kChip, over 6 million microbial communities were screened to identify the "ensemble" of bacteria that neutralises pathogenic S. aureus. Our Solution: At Sequential, we specialise in Microbiome Product Testing to support your business’ goals, such as innovative AD treatments. Our tailored studies and product formulation support ensure developments that maintain microbiome integrity, promoting efficacy, compatibility, and healthier skin. Partner with us to confidently develop microbiome-based topical solutions that address AD’s unique challenges. References: Ağagündüz, D., Gençer Bingöl, F., Çelik, E., Cemali, Ö., Özenir, Ç., Özoğul, F. & Capasso, R. (2022) Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions. Journal of Translational Medicine. 20 (1), 460. doi:10.1186/s12967-022-03609-y. Andrus, E. (2024) Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis. 2024. Concerto Biosciences. https://www.concertobio.com/press/concerto-biosciences-announces-first-participant-dosed-with-live-biotherapeutic-ens-002-in-phase-1-trial-for-atopic-dermatitis [Accessed: 19 November 2024]. Locker, J., Serrage, H.J., Ledder, R.G., Deshmukh, S., O’Neill, C.A. & McBain, A.J. (2024) Microbiological insights and dermatological applications of live biotherapeutic products. Journal of Applied Microbiology. 135 (8), lxae181. doi:10.1093/jambio/lxae181. Totté, J.E.E., van der Feltz, W.T., Hennekam, M., van Belkum, A., van Zuuren, E.J. & Pasmans, S.G.M.A. (2016) Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta‐analysis. British Journal of Dermatology. 175 (4), 687–695. doi:10.1111/bjd.14566.

The ‘exposome’ refers to the complex interplay of environmental exposures that influence the skin over a lifetime, including factors such as pollution, UV radiation and lifestyle choices. Comparable in complexity to the skin microbiome, the exposome represents an exciting frontier in research, with significant implications for skincare innovation and personalised solutions. What We Know: The exposome encompasses a broad range of environmental and lifestyle factors: air pollution, UV radiation, climate, diet, sleep patterns, stress and hormonal changes. Each individual’s exposome is unique, shaped by the combination of these factors over time (Passeron et al., 2020). Key environmental elements such as traffic-related air pollution, hormones, nutrition, stress and sleep significantly impact skin ageing and overall skin health. For example, pollution accelerates pigmentation, wrinkles and eczema, while hormonal fluctuations, poor nutrition and stress contribute to inflammation, collagen degradation and conditions like atopic dermatitis, psoriasis and acne. These factors affect biochemical processes that influence skin ageing and the development of inflammatory skin disorders (Passeron et al., 2020). However, the skin’s exposome has been relatively underexplored and further investigation is needed to understand how these factors interact and the net effects they have on the skin (Krutmann et al., 2017). Industry Impact and Potential: As research into the exposome evolves, the skincare industry is increasingly focusing on how these factors drive skin ageing and health, leading to more personalised, targeted skincare solutions. One framework, called The Skin Interactome, integrates the genome, microbiome and exposome to unravel the molecular mechanisms underlying skin health and ageing (Khmaladze et al., 2020). This holistic approach examines how genetic, environmental and microbial factors work together to influence skin physiology. By identifying key molecular pathways, such as those involved in collagen synthesis, this framework aims to develop targeted strategies to protect skin health and delay the visible signs of ageing (Khmaladze et al., 2020). Pooling research across these distinct areas of skincare is vital, as it provides a comprehensive understanding of how environmental, lifestyle and biological factors collectively influence skin health and ageing. This integrated approach allows for the development of more targeted and effective skincare solutions. Our Solution: Sequential is at the forefront of microbiome research, supported by a database of 20,000 microbiome samples, 4,000 ingredients and a global network of 10,000 testing participants. Our customisable solutions span microbiome studies and product formulation, with a strong focus on preserving biome integrity. Whether exploring the skin, scalp, oral or vulvar microbiome, we are your ideal partner for advancing research. References: Khmaladze, I., Leonardi, M., Fabre, S., Messaraa, C. & Mavon, A. (2020) The Skin Interactome: A Holistic ‘Genome-Microbiome-Exposome’ Approach to Understand and Modulate Skin Health and Aging. Clinical, Cosmetic and Investigational Dermatology. 13, 1021–1040. doi:10.2147/CCID.S239367. Krutmann, J., Bouloc, A., Sore, G., Bernard, B.A. & Passeron, T. (2017) The skin aging exposome. Journal of Dermatological Science. 85 (3), 152–161. doi:10.1016/j.jdermsci.2016.09.015. Passeron, T., Krutmann, J., Andersen, M.L., Katta, R. & Zouboulis, C.C. (2020) Clinical and biological impact of the exposome on the skin. Journal of the European Academy of Dermatology and Venereology: JEADV. 34 Suppl 4, 4–25. doi:10.1111/jdv.16614.

Scalp psoriasis is a common yet often treatment-resistant autoimmune condition that frequently co-occurs with psoriasis in other areas. Currently, the specific influence of the scalp microbiome on scalp psoriasis, and how this can be leveraged for treatment, remains largely unexplored. What We Know: Psoriasis is a chronic inflammatory skin condition affecting 1–3% of the global population, characterised by persistent, scaly plaques. Genetic, environmental and epigenetic factors contribute to its development, with up to 80% of psoriasis patients experiencing scalp involvement (Choi et al., 2024).  Treatments for scalp psoriasis range from topical agents, including steroids and vitamin D analogues, to systemic treatments like methotrexate and cyclosporine. Despite available therapies, managing scalp psoriasis remains complex due to challenges with topical application and variability in patient response (Ghafoor et al., 2022) . Industry Impact and Potential: The skin microbiome of psoriasis patients differs significantly from that of healthy individuals. Psoriatic lesions exhibit increased Staphylococcus  and decreased Cutibacterium  compared to healthy controls. This dysbiosis may cause inflammation, impaired skin barrier functions and autoimmunity (Choi et al., 2024) . Researcher has shown that microbial diversity in the scalp microbiome increased with the severity of scalp psoriasis. Pseudomonas  and Malassezia  species, particularly M. globosa , were more prevalent in severe cases. Malassezia  is linked to several skin conditions, including psoriasis and its lipase activity may disrupt the skin barrier and provoke inflammation (Choi et al., 2024) .  Additionally, the IL-17 pathway, a key player in psoriasis pathogenesis, interacts with Malassezia  to exacerbate skin inflammation. Understanding these microbial changes offers a promising avenue for developing targeted treatments that address the root causes of scalp psoriasis, potentially enhancing patient outcomes (Choi et al., 2024) .  Powered by their Amino M³ Complex,™ @Act + Acre’s Microbiome Cooling Scalp Serum helps balance the scalp microbiome, soothing dryness, itching and reducing dandruff flakes. The formula uses peppermint oil for immediate relief, while amino acids, grape, ginger and frankincense restore microbiota balance and provide long-term protection against irritation. Our Solution: Sequential, with its database of over 20,000 microbiome samples and 4,000 ingredients, offers comprehensive services to evaluate product impacts on the microbiome. Our customizable microbiome studies, combined with real-world testing environments, provide critical insights into product efficacy. By partnering with Sequential, you gain access to data-driven solutions that help optimise your formulations and ensure they support scalp health in line with emerging research. References: Choi, J.-Y., Kim, H., Min, K.-H., Song, W.-H., Yu, D.-S., Lee, M. & Lee, Y.-B. (2024) Bacteria, Fungi, and Scalp Psoriasis: Understanding the Role of the Microbiome in Disease Severity. Journal of Clinical Medicine. 13 (16), 4846. doi:10.3390/jcm13164846. Ghafoor, R., Patil, A., Yamauchi, P., Weinberg, J., Kircik, L., Grabbe, S. & Goldust, M. (2022) Treatment of Scalp Psoriasis. Journal of drugs in dermatology: JDD. 21 (8), 833–837. doi:10.36849/JDD.6498.

What is a Microbiome Formulation? What is a Microbiome Formulation? Less is More approach Statistically, Women typically apply around 16 beauty products each day, exposing their skin to about 515 synthetic chemicals daily. (“The Average Woman Uses 16 Beauty Products Every Day. Here Are the Ones Worth the Investment,” 2018) This extensive exposure has led to a rise in skin sensitivity, which now affects 60-70% of women and 50-60% of men worldwide (Sensitive skins wear their own skin microbiota, 2024) - a number that continues to climb. To mitigate these effects, experts advise using fewer, essential ingredients and prioritising simple, balanced formulations over emphasising single "hero" ingredients. This holistic approach fosters skin compatibility, supporting healthier skin with reduced risk of irritation. Traditional vs Microbiome approach The traditional skin care approach highlights a single, "hero" ingredient or a blend of active ingredients to deliver specific benefits, with the spotlight on these components as the main drivers of product efficacy. However, a microbiome-focused approach takes a broader, more holistic perspective. It considers how each ingredient, including non-active additives (functional ingredients), interacts with the skin and its microbiome. This method aims to create formulations that support the skin's natural microbial balance, ensuring that every component contributes positively to overall skin health. Anhydrous Products Anhydrous products, with no water, do not require preservatives since bacteria need moisture to grow. However, they face challenges: incorporating water-soluble actives is difficult, and they are more prone to oxidation and rancidity. Their thick, oil-based consistency may also not suit all skin types, especially oily or sensitive skin. Despite these drawbacks, anhydrous formulations appeal to consumers interested in preservative-free, minimal skincare. Water-based Products Water in skincare products often makes up 80%, requiring emulsifiers to mix with oils and preservatives to prevent bacterial and fungal growth. To avoid contamination, effective preservation is essential. Instead of skipping preservation, reducing water activity can enhance product stability by limiting moisture, which is crucial for safer, less chemically intensive formulations. pH Maintaining a skincare formulation with a slightly acidic pH, ideally below 5, supports the skin's microbiome and barrier function. Alkaline cleansers with pH levels above 7 can disrupt the acid mantle, weakening the barrier and encouraging harmful bacteria. Hülpüsch et al. (2022) found that a higher skin pH (5.7–6.2) in atopic dermatitis patients is linked to increased Staphylococcus aureus colonisation, worsening inflammation and barrier issues. Acidic formulations may help control bacterial overgrowth, reducing flare-ups and promoting skin health in at-risk groups like those with AD. Ingredients Formulations that are high in lipids can strengthen the skin barrier, enhancing hydration and resilience against irritants. Combining gentle surfactants with super fatty agents further reduces potential for irritation and maintains moisture, which is particularly beneficial for sensitive skin types. These principles help prevent disruption of the microbiome, ensuring the skin remains balanced and resilient over time (Van Belkum et al., 2023). The selection of mildly acidic, pH-balanced ingredients close to the skin’s natural acidity (4.7 < pH < 5.7) is crucial, as it helps preserve the skin’s barrier and microbiome. Preservatives To protect the skin microbiome and reduce bacterial growth, it’s essential to minimise preservatives, especially in oil-based products. Anhydrous formulations, which don’t require preservatives, are ideal when possible. For water-based products, alternatives such as antimicrobial peptides (AMPs), and natural humectants like glycerin, sodium lactate, and NMF components (ceramide, urea), can improve microbial stability and skin barrier function (Halla et al., 2018). Airless packaging and sterilisation methods like UHT technology can further enhance product safety by minimising contamination, reducing the need for traditional preservatives. Surfactants Water-in-oil System: Choose emulsifiers with a low hydrophilic-lipophilic balance ratio and natural ingredients like plant oils or sugars. Limit emulsifier concentration to maintain skin barrier integrity. Avoid Polysorbate 80, which can promote pathogen growth, and use alternatives like Polyglyceryl 4 Oleate, which self-emulsify when mixed with water. Oil-in-water System: Use microbiome-friendly emulsifiers derived from natural sources like plant oils and sugars. Examples include Olivem 1000, made from olive oil (Cetearyl Olivate and Sorbitan Olivate), and Emulium Mellifera MB, which combines beeswax and jojoba wax (Polyglyceryl-6 Distearate and Jojoba Esters). These emulsifiers help maintain skin health while supporting the microbiome. It's also important to limit the concentration of emulsifiers to avoid disrupting the skin barrier. Fragrances/Essential Oils Fragrances should generally be avoided in skincare formulations, especially for sensitive skin, as many fragrances can cause irritation. However, certain essential oils may serve as antimicrobial agents in products for non-sensitive skin, offering a natural alternative to synthetic preservatives. For instance, bergamot and lavender oils demonstrate antibacterial and antifungal effects, particularly against Staphylococcus aureus, though they do not affect S. epidermidis (Kim et al., 2022). Additionally, rosemary oil and phenylethyl alcohol show strong antifungal properties, adding preservative benefits without traditional preservatives. Reference Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018). The human skin microbiome. Nature Reviews Microbiology, 16(3), 143-155. Halla, N., Fernandes, I. P., Heleno, S. A., Costa, P., Boucherit-Otmani, Z., Boucherit, K., Rodrigues, A. E., Ferreira, I. C. F. R., & Barreiro, M. F. (2018). Cosmetics Preservation: A Review on Present Strategies. Molecules, 23(7), 1571. https://doi.org/10.3390/molecules23071571 The average woman uses 16 beauty products every day. Here are the ones worth the investment. (2018, December 6). The Telegraph. https://www.telegraph.co.uk/beauty/face/essential-skincare-makeup-products-use-everyday/ Sensitive skins wear their own skin microbiota - BEAUTY HORIZONS 1 2021 WW. (2024, March 27). https://digital.teknoscienze.com/beauty_horizons_1_2021_ww/sensitive_skins_wear_their_own_skin_microbiota Hülpüsch, C., Tremmel, K., Hammel, G., Bhattacharyya, M., De Tomassi, A., Nussbaumer, T., Neumann, A. U., Reiger, M., & Traidl‐Hoffmann, C. (2020). Skin pH–dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity. Allergy, 75(11), 2888–2898. https://doi.org/10.1111/all.14461 Van Belkum, A., Lisotto, P., Pirovano, W., Mongiat, S., Zorgani, A., Gempeler, M., Bongoni, R., & Klaassens, E. (2023). Being friendly to the skin microbiome: Experimental assessment. Frontiers in Microbiomes, 1. https://doi.org/10.3389/frmbi.2022.1077151 Nielsen, H. L., et al. (2016). Influence of emulsifiers on microbial stability in cosmetic formulations. International Journal of Cosmetic Science, 38(4), 357-366. https://doi.org/10.1111/ics.12301 Kim, J., et al. (2022). Antimicrobial effects of essential oils on skin microbiota. Journal of Cosmetic Science, 73(5), 452-460.

What Disrupts the Skin Microbiome? What Disrupts the Skin Microbiome? The skin microbiome is an intricate ecosystem of bacteria, fungi, and viruses that protect and maintain skin health (Smythe & Wilkinson, 2023). It acts as a defence against harmful pathogens, regulates inflammation, and supports the skin’s overall barrier function. However, disruptions to this microbiome can eventually lead to skin issues like acne, eczema, and various skin infections (Wallen-Russell, 2019). Understanding these disruptions is key to making informed choices about skincare, diet, and lifestyle to promote healthy skin. 1. Harsh Skincare Products Personal care products like soaps and lotions can disrupt the skin microbiome by removing natural oils and beneficial microbes. Many contain harsh chemicals, such as preservatives and fragrances, which reduce microbial diversity and promote the growth of harmful bacteria like Staphylococcus aureus. A study by Wallen-Russel (2018) found that synthetic ingredients generally lower the positive effects on skin biodiversity. Using essential, pH-balanced skincare products is recommended to maintain a healthy skin microbiome. 2. Antibiotics and Medications The use of antibiotics is a major disruptor of the skin microbiome. While antibiotics are essential for treating bacterial infections, their overuse or misuse can eliminate beneficial bacteria alongside harmful pathogens. This disruption can lead to a decrease in microbial diversity and the dominance of antibiotic-resistant bacteria, which may contribute to skin conditions like eczema and psoriasis. Studies have shown that prolonged antibiotic use can have lasting effects on the skin's microbial communities, making it more prone to dysbiosis and related diseases (Byrd et al., 2018). 3. Environmental Factors Environmental exposures are a major cause of skin microbiome disruption. Pollution, particularly airborne particulate matter and toxins, weakens the skin barrier and alters microbial diversity by causing oxidative stress and inflammation. This imbalance favours harmful microbes while reducing beneficial ones. Araviiskaia et al. (2019) found that chronic inflammatory skin conditions like eczema and psoriasis tend to worsen in individuals, including children, when exposed to high pollution levels. While moderate sun exposure is beneficial, excessive UV exposure can cause acute and chronic skin damage, including inflammation, premature ageing, and increased cancer risk. Patra, Sérézal & Wolf (2020) highlights how UV radiation disrupts the skin microbiome, potentially leading to dysbiosis and compromised skin health. 4. Diet and Lifestyle Diet and lifestyle choices can also direct the overall health of the skin microbiome. Ghosh, McMahon & Lappin (2021) revealed that a plant-based diet can positively influence the skin microbiome, reducing inflammation and oxidative stress, thereby supporting overall skin health. Conversely, diets high in processed foods and saturated fats can negatively impact the microbiome and lead to health issues, including skin conditions. 5. Stress and Hormonal Changes Stress can significantly impact the skin microbiome, primarily through hormonal and behavioural changes. Stress activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to increased production of cortisol and other stress hormones. This hormonal response can cause inflammation and immune dysregulation, which may exacerbate various skin conditions like psoriasis, eczema, and acne. Additionally, stress can lead to changes in behaviour, such as neglecting skincare routines or engaging in unhealthy habits (e.g., smoking, poor diet) that further disrupt the skin microbiome (Holmes et al., 2015). Reference Araviiskaia, E., Berardesca, E., Bieber, T., Gontijo, G., Sanchez Viera, M., Marrot, L., Chuberre, B., & Dreno, B. (2019). The impact of airborne pollution on skin. Journal of the European Academy of Dermatology and Venereology : JEADV, 33(8), 1496–1505. https://doi.org/10.1111/jdv.15583 Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018). The human skin microbiome. Nature Reviews Microbiology, 16(3), 143-155. https://doi.org/10.1038/nrmicro.2017.157 Ghosh, S., McMahon, A., & Lappin, D. F. (2021). The relationship between diet, gut microbiota, and skin health. Nutrients, 13(5), 1568. Holmes, C. J., Plichta, J. K., Gamelli, R. L., & Radek, K. A. (2015). Dynamic Role of Host Stress Responses in Modulating the Cutaneous Microbiome: Implications for Wound Healing and Infection. Advances in wound care, 4(1), 24–37. https://doi.org/10.1089/wound.2014.0546 Patra, V., Sérézal, I. G., & Wolf, P. (2020). Potential of Skin Microbiome, Pro- and/or Pre-Biotics to Affect Local Cutaneous Responses to UV Exposure. Nutrients, 12(6), 1795. https://doi.org/10.3390/nu12061795 Smythe, P., & Wilkinson, H. N. (2023). The skin microbiome: Current landscape and future opportunities. International Journal of Molecular Sciences, 24(4), 3950. https://doi.org/10.3390/ijms24043950 Wallen-Russell, C. (2018). The role of Every-Day Cosmetics in Altering the skin Microbiome: A study using biodiversity. Cosmetics, 6(1), 2. https://doi.org/10.3390/cosmetics6010002 Wallen-Russell, C. (2019). The impact of skin care products on skin chemistry and microbiome dynamics. BMC Biology, 17(1), 47. https://doi.org/10.1186/s12915-019-0660-6

< Back Head of Growth East Coast of the United States, USA Job Type Full Time Workspace Hybrid About the Role As the Head of Growth for Sequential, you will play a pivotal role in driving the commercial success of our microbiome-focused products and services. Your responsibilities will include marketing, sales, and business development, with a focus on expanding market share, increasing revenue, and creating and managing a high-performing, engaged team. You will be responsible for setting and executing strategic sales plans, managing key customer relationships, tracking team performance through defined KPIs, and collaborating with product, marketing, and operations teams to ensure alignment with Sequential’s growth goals. A strong understanding of the microbiome industry and current market trends is essential to maximize client impact and drive Sequential’s mission forward. Essential Duties and Responsibilities: Develop and execute comprehensive commercialization strategies to achieve ambitious growth objectives. Drive business growth through acquiring new customer accounts, expanding relationships with existing clients, and identifying new market segments. Identify and secure strategic partnerships within the biotechnology, microbiome, cosmetics, and pharmaceutical industries to accelerate market expansion and visibility. Manage and conduct high-level negotiations with senior executives to secure key accounts and establish long-term partnerships. Set ambitious revenue targets and design and implement actionable plans to meet or exceed them, including pricing strategies and go-to-market plans. Team Leadership: Build, lead, and develop a high-performing sales team, fostering a collaborative, results-oriented culture with a focus on accountability and continuous learning. Conduct ongoing market research and competitor analysis to keep strategies competitive and adaptive. Customer Relationship Management and Retention: Strengthen client relationships with a focus on long-term partnerships and retention through exceptional service and communication. Cross-functional Collaboration: Partner with product development, marketing, and operations teams to ensure sales strategies align with company goals and product offerings. Data-Driven Strategy: Use data and analytics to monitor performance, optimize strategies, and inform sales decisions, including regular performance reporting to senior leadership and investors. Remote Work: Primarily remote, with a willingness to meet at our lab in NYC on a monthly basis. Qualifications and Experience: 5+ years of sales or growth leadership experience, preferably in the microbiome, biotechnology, cosmetics, or pharmaceutical fields, though exceptional candidates with less experience will be considered based on performance and potential. Proven track record of exceeding sales targets, driving business development, and managing key client accounts effectively in a startup or scale-up environment. Hands-on experience and proficiency with CRM systems, particularly HubSpot, and data-driven sales methodologies. Strong written and verbal communication skills with the ability to present complex scientific and technical information in a clear and compelling way. Tech-savvy, with a passion for leveraging technology and automation to drive sales success. Demonstrated strategic mindset, with strong analytical skills for tracking performance metrics and adjusting strategies to maximize revenue. MSc/PhD in Life Sciences is preferred; senior sales experience in a commercial environment within Cosmetics, Pharma, or Biotech is advantageous. Exceptional client relationship-building skills with a focus on fostering long-term partnerships. Experience in a Series A/B growth phase or startup environment, with a focus on scaling revenue operations and market presence. Key Attributes for Success: Entrepreneurial mindset with a proactive, results-driven approach. Ability to balance strategic vision with hands-on execution. Adaptability and resilience in a fast-paced, evolving market landscape. Strong leadership, mentoring, and talent development capabilities. What you get from us: Attractive Compensation: A competitive base salary paired with a significant commission structure, rewarding your success and drive. Ownership & Growth: Participate in our Equity Incentive Plan with share options, ensuring you're central to Sequential’s growth and success. Industry-Leading Innovation: Be part of one of the fastest-growing biotech companies in the microbiome industry, where cutting-edge science meets real-world impact every day. About the Company Sequential is a global leader in the skin microbiome field, a team of PhD experts in testing products and their effect on the human microbiome (skin, scalp, oral, vulva). An Innovate UK- and Enterprise Singapore-backed company, with labs in London, New York City and Singapore. Awarded the title "Most Significant" Testing Solution in the Industry - (C&T, 2022). To date, Sequential has amassed over 25,000 human skin microbiome samples and corresponding formulations tested in vivo on the skin. With this vast genomic dataset, Sequential are figuring out optimal formulations that could potentially alleviate skin conditions, for example – acne, atopic dermatitis and rosacea. They have been supported by Innovate UK, Enterprise SG, A*STAR (Genome Institute of Singapore). They have raised $4.3MM USD to date from SOSV, Metaplanet, Scrum Ventures, Corundum Systems Biology and are a resident company of JLABS Innovation (in NYC). Apply Now